Drug Trial Radar · NCT06433505
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 30, 2024
Primary completion
Feb 14, 2025
Study completion Feb 28, 2025
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
Conditions
- Healthy Volunteers
Interventions
BMS-986365Drug
Specified dose on specified days
[14C] BMS-986365Drug
Specified dose on specified days.
[14C] BMS-986409 + BMS-986410Drug
Specified dose on specified days
[14C] BMS-986410 + BMS-986409Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to Day 60
- Time of maximum observed concentration (Tmax)Time frame: Up to Day 60
- Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 60
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC (INF))Time frame: Up to Day 60
- Apparent terminal plasma half-life (T-HALF)Time frame: Up to Day 60
- Total body clearance (CLT)Time frame: Up to Day 15
- Apparent total body clearance (CLT/F)Time frame: Up to Day 60
- Mean residence time (MRT)Time frame: Up to Day 15
- Apparent volume of distribution (Vz)Time frame: Up to Day 15
- Apparent volume of distribution (Vz/F)Time frame: Up to Day 60
- Absolute bioavailability (F)Time frame: Up to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.